Other Clinical Trial - Clinical Study of Neoadjuvant Chemotherapy &

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05557552` - Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer	N/A
Active, not recruiting	`NCT04765709` - Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC	Phase 2
Not yet recruiting	`NCT06449313` - Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer	Phase 2
Not yet recruiting	`NCT06031597` - Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy	Phase 3
Recruiting	`NCT04728724` - Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer	Phase 2
Not yet recruiting	`NCT05451173` - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC	Phase 1/Phase 2
Completed	`NCT06015815` - The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
Completed	`NCT03728556` - A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer	Phase 3
Recruiting	`NCT04586465` - Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC	Phase 2
Not yet recruiting	`NCT05548504` - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC	Phase 2
Completed	`NCT02434081` - NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma	Phase 2
Not yet recruiting	`NCT02946216` - ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC	N/A
Completed	`NCT03550482` - Oncoxin® and Quality of Life in Cancer Patients	Phase 4
Recruiting	`NCT05398094` - Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy	Phase 2
Completed	`NCT02418234` - T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure	N/A
Recruiting	`NCT05338619` - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy	Phase 2
Not yet recruiting	`NCT05414630` - A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer	Phase 2
Withdrawn	`NCT04941365` - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy	N/A
Not yet recruiting	`NCT06463665` - Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)	Phase 2
Recruiting	`NCT04878952` - Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer	N/A

NCT number	NCT04699721
Study type	Interventional
Source	Xiangya Hospital of Central South University
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	July 1, 2020
Completion date	December 2027

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms